Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608878 | 0.90 | TDP1 (0.54) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL2098501 | 0.88 | TDP1 (0.55) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL2608867 | 0.83 | CHRM2 (0.48) | CHRNA7L3MBTL1TDP1CHRNB2CHRNA4 | |
| SCHEMBL24925632 | 0.81 | TDP1 (0.58) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL22161582 | 0.79 | L3MBTL1 (0.61) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL12793983 | 0.79 | CHRNA7 (0.52) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL58302 | 0.78 | AOC3 (0.43) | NPC1RAB9A | |
| SCHEMBL13798116 | 0.78 | TDP1 (0.54) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL4812510 | 0.77 | CHRNA7 (0.53) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 | |
| SCHEMBL273379 | 0.77 | CHRNA7 (0.57) | CHRNA7L3MBTL1TDP1CYP2A6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | CHRNA7 4092/4885L3MBTL1 2460/4885TDP1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.